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Abstract 
Background: As emergency response to the Ebola epidemic, the Government of Sierra Leone and its partners 
implemented a large‑scale Mass Drug Administration (MDA) with artesunate–amodiaquine (ASAQ) covering >2.7 mil‑
lion people in the districts hardest hit by Ebola during December 2014–January 2015. The World Health Organization 
(WHO) and the National Malaria Control Programme (NMCP) evaluated the impact of the MDA on malaria morbidity 
at health facilities and the number of Ebola alerts received at District Ebola Command Centres.
Methods: The coverage of the two rounds of MDA with ASAQ was estimated by relating the number anti‑malarial 
medicines distributed to the estimated resident population. Segmented time‑series analysis was applied to weekly 
data collected from 49 primary health units (PHUs) and 11 hospitals performing malaria parasitological testing during 
the study period, to evaluate trends of malaria cases and Ebola alerts during the post‑MDA weeks compared to the 
pre‑MDA weeks in MDA‑ and non‑MDA‑cheifdoms.
Results: After two rounds of the MDA, the number of suspected cases tested with rapid diagnostic test (RDT) 
decreased significantly by 43 % (95 % CI 38–48 %) at week 1 and remained low at week 2 and 3 post‑first MDA and at 
week 1 and 3 post‑second MDA; RDT positive cases decreased significantly by 47 % (41–52 %) at week 1 post‑first and 
remained lower throughout all post‑MDA weeks; and the RDT test positivity rate (TPR) declined by 35 % (32–38 %) at 
week 2 and stayed low throughout all post‑MDA weeks. The total malaria (clinical + confirmed) cases decreased sig‑
nificantly by 45 % (39–52 %) at week 1 and were lower at week 2 and 3 post‑first MDA; and week 1 post‑second MDA. 
The proportion of confirmed malaria cases (out of all‑outpatients) fell by 33 % (29–38 %) at week 1 post‑first MDA and 
were lower during all post‑MDA weeks. On the contrary, the non‑malaria outpatient cases (cases due to other health 
conditions) either remained unchanged or fluctuated insignificantly. The Ebola alerts decreased by 30 % (13–46 %) at 
week 1 post‑first MDA and much lower during all the weeks post–second MDA.
Conclusions: The MDA achieved its goals of reducing malaria morbidity and febrile cases that would have been 
potentially diagnosed as suspected Ebola cases with increased risk of nosocomial infections. The intervention also 
helped reduce patient case‑load to the severely strained health services at the peak of the Ebola outbreak and malaria 
transmission. As expected, the effect of the MDA waned in a matter of few weeks and malaria intensity returned to 
the pre‑MDA levels. Nevertheless, the approach was an appropriate public health intervention in the context of the 
Ebola epidemic even in high malaria transmission areas of Sierra Leone.
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Background
Malaria transmission in Sierra Leone, with a population of 
6.3 million [1], is intense with little seasonal fluctuations. 
Recent surveys have documented high parasite preva-
lence (43  % in children under five) [2] and high under-
five child mortality (156 per 1000 live birth) [3]. In 2013, 
prior to the Ebola viral disease (EVD) outbreak, the coun-
try scaled-up anti-malarial interventions and, as a result, 
62 % of households owned at least one long-lasting insec-
ticidal net (LLIN) and 39 % of the population slept under 
an LLIN the night before the survey; 37 % of children with 
fever took artemisinin-based combination therapy (ACT) 
[2]; and  >85  % of the suspected cases in the public sec-
tor were parasitologically tested [4]. In June 2014, over 3.5 
million LLINs were distributed targeting the entire popu-
lation. In 2014, Sierra Leone became the worst affected 
country by the Ebola outbreak, with   >8704 confirmed 
cases; and >3589 deaths as of 3rd November 2015 when 
WHO certified the country Ebola-free [5].
At the same time malaria burden exerted a heavy toll to 
the health care system, which was compromised by the 
EVD epidemic due to high mortality to frontline health 
workers and closure of many facilities both in the public 
and private sectors. Fear of being referred to Ebola hold-
ing centres and of contracting EVD nosocomial infections 
significantly reduced patient attendance to health facili-
ties by up to 40 % from May to September 2014, but the 
attendance returned to normal (only 7 % less) by Decem-
ber 2014 [6]. The similarities of the initial clinical presen-
tations of EVD with that of malaria, i.e., fever, anorexia, 
fatigue, headache and joint pains posed a problem of dif-
ferential diagnosis for both patients and health care work-
ers. As a result, patients with symptoms of malaria had 
been shunning away from seeking care for fear of being 
suspected as EVD and referred to Ebola holding centres—
leading to increased malaria morbidity and mortality for 
lack of prompt diagnosis and effective treatment. Recent 
estimates showed that absence of regular access to health 
care services during the Ebola epidemic, may have led to 
an increase of untreated malaria cases by 88 % (95 % CI 
83–93) or 207 per 1000 population in Sierra Leone, equiv-
alent to 1.3 million (0.9–1.9 million) untreated cases [7]. A 
similar estimate in Guinea showed increase in the number 
of malaria cases as a result of changes in health-seeking 
behaviour caused by the Ebola epidemic [8].
In response to the Ebola outbreak and its impact on the 
malaria burden, WHO issued an interim recommendation 
for malaria prevention and control in EVD disease-affected 
zones in November 2014. WHO recommended changes 
in testing practices promoting use of personal protective 
equipment in health facilities and “no touch” approach at 
community level, new approaches for LLINs distribution 
to avoid exposure to EVD due to overcrowding and MDA 
using ACT in areas heavily affected by Ebola, where malaria 
transmission is high and access to treatment is very low [9]. 
As an emergency response, the MoHS instructed MDA 
and presumptive treatment of all Ebola suspected cases in 
the Holding centres with ASAQ (Coarsucam™) without 
parasitological testing (Additional file 1). The objectives of 
the MDA were to rapidly reduce (i) malaria burden and (ii) 
the number of febrile cases which could be considered as 
suspected EVD cases and referred to Ebola Holding Cen-
tres, increasing the risk of nosocomial infection. The MDA 
did not aim for a long-term reduction of malaria transmis-
sion in the areas.
The NMCP of the Ministry of Health and Sanitation 
(MoHS), in collaboration with Médecins Sans Frontières 
(MSF) Spain, United Nations Children’s Fund (UNICEF), 
The Global Fund to Fight HIV/AIDs, Tuberculosis and 
Malaria (GFATM) and WHO led a large scale of MDA using 
ASAQ-the first-line antimalarial medicine in the country.
The MDA involved micro-planning at district level 
with participation of local authorities (paramount chiefs, 
councillors, primary health unit in-chiefs, regional 
and national supervisors); and major partners includ-
ing MSF-Spain, UNICEF and WHO. Quantification of 
ASAQ needs was conducted based on the house-to-
house population registration previously conducted for 
the LLIN mass campaign in 2014 using four age catego-
ries (2  % for 6–11  months; 13.7  % for 12–59 months; 
28 % for 5–13 years; 54.3 % for 14 years and above). The 
two rounds of MDA targeted to cover at least 85  % of 
the three million people living in Ebola affected districts 
(with at least 85  % adherence to treatment) and were 
implemented at 5 weeks interval during, 5–8 December 
2014 and 16–19 January 2015.
Funding for the procurement of six million ASAQ 
doses and operational costs was provided by partners. 
Quality control analysis of ASAQ samples was under-
taken by the Pharmacy Board of Sierra Leone.
Administration of ASAQ was carried out in four regi-
mens, door-to-door, with directly-observed treatment 
(DOT) for the first dose with counselling to complete the 
full 3-day treatment courses without supervision. The 
MDA campaign excluded: (1) children below 6 months, (2) 
malnourished children, (3) pregnant women in their first 
trimester; persons with fever or feeling unwell, (4) persons 
who received ASAQ within the last month, and (5) patients 
taking Zidovudine, Efavirenz or co-trimoxazole. Family 
members in quarantined households (with confirmed or 
suspected Ebola cases) were not visited by the MDA cam-
paign but were counted and provided with ASAQ by the 
Ebola surveillance teams with personal protective equip-
ment (PPE) following the standard safety procedures.
A total of 8330 health staff and community health work-
ers (CHWs) were trained and deployed for the campaign, 
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of which 5000 CHWs were in the capital, Western Area, 
alone. Distribution teams (each comprising a health worker 
from the nearest health facility and a CHW) visited at least 
150 persons/day for 4 days. Supervision was conducted by 
48 national and 833 district supervisors. In addition, 70 
independent monitors visited 8400 households in 4  days 
and assessed the coverage and quality of the MDA during 
the campaign (In-process) and immediately after (End-
process); and 33 health staff specifically trained in phar-
macovigilance interviewed a total of about 19,000 persons 
after each cycle and recorded reports of adverse effects.
Intensive social mobilization before and during the 
MDA campaign included advocacy meetings with local 
stakeholders; press briefing, jingle slots on national 
radios and local FMs and TV panel discussions; posters 
and banners; megaphone-mounted vehicles and town 
criers. Key messaging focussed on benefits of ASAQ to 
reduce fever and how to avoid possible confusion with 
Ebola suspects; expected common side effects of ASAQ; 
importance of adherence to treatment; beneficiary and 
excluded groups; and what to do and where to report in 
event of suspected adverse drug reaction.
Given the scope of the MDA as emergency measure to 
reduce the burden of malaria in the context of the Ebola out-
break, its unprecedented large scale in Africa, and the signif-
icant investments made, WHO and NMCP collaborated to 
evaluate the impact of the MDA on malaria morbidity and 
burden of cases presenting as Ebola suspected patients.
This study aimed to primarily assess the impact of the 
MDA on trends of number of malaria cases attending 
health facilities in the chiefdoms (sub-districts) targeted 
for MDA; and of suspected Ebola alerts.
Methods
Ethical clearance
The study was approved by the NMCP, Ministry of 
Health and Sanitation and involved only the use of anon-
ymous aggregated data collected routinely by the health 
facilities and Ebola alert calls made to the Ebola Com-
mand Centres (temporarily established in each district in 
response to the Ebola outbreak).
The impact of the two MDA rounds was evaluated 
using reported data on:
1. suspected cases tested with RDT tests, malaria con-
firmed cases and RDT test positivity rate (TPR) at 
health facility level.
2. Ebola alerts reported to the Ebola Command Cen-
tres.
Interventions and sites
MDA was implemented in the eight (of the total 14 dis-
tricts in the country) that are highly endemic to malaria 
but also  were affected by the Ebola outbreak. In six of 
them, MDA was implemented only in the chiefdoms (the 
lowest administrative unit) with confirmed Ebola cases. 
Chiefdoms with no confirmed Ebola case were excluded 
from the MDA. In the two districts of Western Area (the 
Capital city, Freetown), however, all zones (equivalent 
to chiefdoms in the rural areas) except two were cov-
ered with MDA in both rounds. The two zones were not 
covered in the first round of MDA due to stock-outs of 
ASAQ.
As controls, chiefdoms that did not have confirmed 
Ebola cases at the time of the MDA, and hence did not 
receive MDA (non-MDA chiefdoms), were selected from 
the same districts to ensure that both the MDA- and 
non-MDA-chiefdoms share similar epidemiological con-
ditions, i.e., similar intensity of malaria transmission and 
programme coverage.
Coverage and utilization of LLINs was assumed con-
stant throughout the Ebola outbreak as the LLIN mass 
campaign was conducted nationwide in June 2014, just 
before the Ebola outbreak [10]. Other factors which may 
have changed over time during pre- and post-MDA have 
affected equally the MDA-chiefdoms and non-MDA-
chiefdoms in the same districts. Access to RDTs and 
ASAQs at community level was suspended, but available 
at health facility level although utilization rates may have 
varied. In the Ebola holding centres, all suspected cases 
received full presumptive anti-malarial treatment courses 
with ASAQ (Additional file 1).
The analysis of impact of MDA on malaria and Ebola-
related parameters was made based on comparing the 
trends of pre- and post-intervention periods.
The coverage of the MDA in each round was calculated 
as the total number of full ASAQ treatment courses dis-
tributed divided by the total number of people targeted for 
MDA multiplied by 100. Target population was determined 
based on the Household Registration used for the 2014 
LLINs mass campaign [10]. The coverage of MDA under 
DOT was calculated as the total number of people who took 
the first dose of the medicine under DOT on the day of visit 
by the drug distributors divided by total number of people 
who received full treatment courses multiplied by 100.
Sampling
Of the 75 health facilities sampled, 65 health facilities had 
complete data for the analysis. The number of facilities in 
the non-MDA chiefdoms was limited to 16 because there 
were only 16 chiefdoms not covered by the MDA. The list 
of the MDA- and non-MDA-chiefdoms in the MDA tar-
geted districts is shown in Table1.
The inclusion criteria for the sample health facilities 
were: (1) primary health units (PHUs) providing testing 
services with RDTs (®First Response Pf Pan); (2) hospitals 
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with inpatient and laboratory services (malaria microscopy 
or RDTs); and (3) viral haemorrhagic fever (VHF) labora-
tories serving Ebola holding centres and treatment cen-
tres. One health centre per chiefdom was selected based 
on random sampling from the sampling list of functioning 
health centres with diagnostic services in each chiefdom. 
Health centres with incomplete data were replaced by 
other health centres from the same chiefdom.
Age groups
Data forms were designed to collect data by three age 
groups, i.e., 6–59 months, 5–13 years and 14+ years old.
Study period
Data collected covered 8  weeks prior to the 1st round of 
MDA (as baseline) and 8 weeks post the 2nd round of MDA 
(2nd week of October 2014 to 1st week of March 2015).
Representativeness
The case series recorded in the selected health facilities 
are assumed to represent the population living in the 
respective catchment area (Chiefdom).
Reporting completeness and data quality
The daily registers were validated and aggregated to 
weekly data by field surveyors. The selected facilities had 
a minimum of 20 complete weekly data out of the total 
25 study period weeks for confirmed outpatient malaria 
cases and inpatient malaria cases.
Data elements
The following data elements were collected from the 
sample health facilities:
 1. Outpatient all-cause consultations (all-cause 
OPD)—number of patients visiting out-patient clinic 
or ward.
 2. Outpatient malaria cases (OPD malaria)—number 
of cases registered as either probable (based on clini-
cal presentation in the absence of testing) and cases 
confirmed with either microscopy or RDT.
 3. Suspected cases tested—number of suspected cases 
tested with either malaria microscopy or RDT.
 4. Confirmed malaria cases—number of positive cases 
confirmed with either malaria microscopy or RDT.
 5. Inpatient all-cause cases (all-cause IPD)—number of 
patients admitted for different health conditions to 
the hospital.
 6. Inpatient malaria case (IPD malaria)—number of 
severe malaria cases admitted. Most of the inpatient 
malaria cases are assumed to be confirmed either at 
the admission or after the patient has been admitted 
although some may be admitted on clinical basis.
 7. Ebola alert—number of phone calls received 
at the 117 free hotline at District Ebola Central 
Command from individuals with suspected Ebola 
symptoms.
 8. Ebola suspected case—any person, alive or dead, suf-
fering or having suffered from a sudden onset of high 
fever and had contact and or cared for a suspected, 
probable or confirmed Ebola case, or a dead or sick 
animal, attended a funeral of someone with Ebola 
or any person with sudden onset of high fever and 
at least three of the following symptoms: headache, 
vomiting, anorexia/loss of appetite, diarrhoea, leth-
argy, stomach pain, aching muscles or joints, swal-
lowing difficulties, breathing difficulties, or hiccup; 
or any person with unexplained bleeding OR any 
sudden, unexplained death [11].
 9. Ebola confirmed case—a probable case  (any sus-
pected case evaluated by a clinician or any deceased 
suspected case having an epidemiological link with a 
confirmed case) or a sample from a person tests pos-
itive for Ebola virus with polymerase chain reaction 
(PCR) in the laboratory.
 10. Ebola negative case—a sample from  a probable or 
suspected person who tests negative for Ebola virus 
with two consecutive PCR tests in the laboratory.
Table 1 List of MDA-chiefdoms and non-MDA-chiefdoms by district
Region Districts MDA chiefdoms Non-MDA chiefdoms (control)
Northern Bombali Bombali Shebora, Makari Gbanti, Makeni, Township Biriwa, Safroko Limba
Port Loko Buya Romende, Kaffu Bullom, Koya, Maforki, Marampa, Masimera, 
BKM
Sanda Magbolonthor, TMS
Tonkolili Kholifa Rowalla, Tane Gbonkolenken, Kholifa Mabang
Koinadugu Wara‑wara Yagala, Sengbeh, Neine Wara‑wara Bafodia, Kasonko
Kambia Mambolo, Samu Braimaia, Magbema
Southern Moyamba Lower Banta, Kori Kayamba, Fakunya
Western Area Urban Western Area Urban Twenty (20) zones Moyiba (Zone5), Zone11 (both low MDA coverage)
Rural Ten (10) zones Hamilton, Goderich
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In addition, the following additional indicators were 
generated and analyzed:
1. test positivity rate (TRP)—positive malaria RDTs 
divided by tested cases multiplied by 100,
2. non-malaria outpatients—all-cause outpatient con-
sultations minus confirmed malaria cases,
3. non-malaria admissions—all-cause admissions 
minus malaria admissions,
4. proportion of outpatient malaria—confirmed out-
patient malaria cases divided by all-cause outpatient 
cases multiplied by 100 and,
5. proportion of malaria admissions—inpatient malaria 
cases divided by all-cause admissions (inpatient 
cases) multiplied by 100.
Data management and statistical methods
An Excel daily data collation tool with automated data 
merging features and paper forms, consistent with the 
Excel daily data forms were used for the field data collec-
tion. Stata 14 [12] was used to compile data by week to 
perform statistical analysis. Trends in indicators related 
to malaria and Ebola alerts were analysed for the pre- 
and post-MDA periods. The impact during each of the 
4  weeks post-MDA was analysed although the impact 
at the 3rd week after each MDA round is the expected 
maximal impact considering the half-life of the medicine 
(amodiaquine). Change in indicators over time (pre- and 
post-MDA) stratified by MDA and non-MDA chiefdoms 
were assessed as relative percent change using a seg-
mented (interrupted time series) regression model. The 
relative percent change was calculated by comparing the 
slop trend in the pre-MDA weeks to the slop predicted 
during post-MDA weeks, assuming a continuation of the 
pre-MDA trend if there were no MDA. The 95 % confi-
dence intervals (CI) around the estimates were computed 
by using the CIs around the regression coefficient esti-
mates using the delta method [13]. Confidence intervals 
not including zero value are interpreted as statistically 
significant change with either decrease (negative inter-
vals) or increase (positive intervals) compared to pre-
MDA trends.
The application of the segmented-time series regres-
sion model is described in (Additional file 2).
Comparisons
1. Pre-MDA versus post-MDA—changes comparison of 
the trends during pre-MDA versus post-MDA peri-
ods, stratified by MDA and non-MDA-chiefdoms.
2. MDA versus non-MDA—chiefdoms—comparison of 
trends in the MDA-chiefdoms versus the non-MDA-
chiefdoms from the same districts.
3. Non-malaria diseases—comparison of trends of 
malaria versus non-malaria outpatient cases and 
admissions during pre-MDA versus post-MDA 
period in both the MDA- and non-MDA-chiefdoms.
Results
Coverage of the intervention (MDA)
The districts and chiefdoms (within the targeted districts) 
that were covered with MDA are shown in Fig. 1.
The coverage of the MDA in the targeted 24 chief-
doms in six rural districts; and 30 zones in the Western 
Area, Freetown (10 zones in the Rural and 20 in Urban 
areas) was 87 % in the first round and 96 % in the sec-
ond round (Table 2). The targeted population for West-
ern Area was particularly under estimated due to lack 
of up-to-date population census-leading to stock out of 
ASAQ for two zones (Zone 5 and 11 in the urban areas) 
in the first round. This was less a problem in the rural 
areas because of the stable population. The coverage of 
DOTs, measured only in the second round, was 71  % 
as the data collection forms in the first round did not 
include DOTs.
Impact of the MDA
The impact of the two rounds of the MDA on the malaria 
burden and suspected Ebola cases measured in the rela-
tive percent changes of the trends of key indicators at 
each of the 4 weeks following the two rounds of the MDA 
are presented in Table  3. The relative percent changes 
during the post-MDA period compared to the trends of 
the pre-MDA period are expressed in percentages with 
95  % CI in brackets. Confidence intervals that exclude 
zero are interpreted as statistically significant change 
(Additional file 3).
Changes in the MDA-chiefdoms during the post-MDA 
weeks
After two rounds of the MDA, the number of suspected 
cases tested with RDT decreased significantly by 43  % 
(95 % CI 38–48 %) at week 1 and remained significantly 
low at week 2 and 3 post-first MDA and at week 1 and 
3 post-second MDA; RDT positive cases decreased sig-
nificantly by 47  % (41–52  %) at week 1 and remained 
lower at all the weeks post-first and second MDA; RDT 
test positivity rate (TPR) declined by 35 % (32–38 %) at 
week 2 and stayed significantly low at all the weeks of 
post-first and second MDA (Table 3; Fig. 2a–c). Confi-
dence intervals are shown in Additional file 3. The total 
malaria (clinical  +  confirmed) cases decreased signifi-
cantly by 45  % (39–52  %) at week 1 and were lower at 
week 2 and 3 after the first MDA; and week 1 after the 
second MDA. The proportion of confirmed malaria 
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cases (of all-outpatients) fell by 33 % (29–38 %) during 
all the 4  weeks of post-first and second MDA. On the 
contrary the non-malaria outpatient cases (cases due to 
other health conditions) either remained unchanged or 
fluctuated insignificantly during the observation weeks 
(Table 3; Fig. 3a–d).
The Ebola alerts (117 hotline calls) in the District Ebola 
Command Centres decreased significantly by 30 % (13–
46 %) at week 1 after the first MDA and by much lower 
during all the weeks after the second MDA (Table  3; 
Fig. 2d and Additional file 3).
The number of malaria inpatient cases decreased sig-
nificantly by 31 % (22–39 %) and 20 % (7–32 %) at week 
1 and 2 post-first MDA respectively. The proportion of 
inpatient malaria (of all inpatients) fell by 24 % (12–35 %) 
at week 1 and by 16  % (0.4–31  %) at week 2 post-first 
MDA. The total inpatient cases in the hospitals did not 
change during the same period (Table 3) except at week 3 
post-first MDA.
Changes in the non-MDA-chiefdoms during the post-MDA 
weeks
The number of suspected cases tested with RDT 
decreased by 23 % (17–30 %) at week 1 and remained low 
at all the weeks after the first and second MDA; the num-
ber of RDT positive cases decreased by 30 % (22–38 %) 
during week 1 post-first MDA and stayed low throughout 
all the post-MDA weeks (except week 2 post-first MDA); 
the decrease in RDT test positivity rate (TPR) was low 
but significant at week 1 and 4 of post-first MDA and 
week 1 of second MDA (Table 3 and Fig. 2a–c). The total 
malaria (clinical  +  confirmed) cases decreased signifi-
cantly in all the weeks post-first and second MDA except 
the second week post-first MDA; the proportion of con-
firmed malaria cases (of all-cause outpatient cases) fell by 
33 % (25–40 %) at week 1 and stayed low at week 3 post-
first MDA and all weeks post-second MDA. The changes 
in the non-malaria outpatient cases during the first MDA 
weeks fluctuated inconsistently (Table  3; Fig.  3a–d) but 
were insignificant throughout all the post-second MDA 
weeks.
Predicted Ebola alerts (117 hotline calls) in the non-
MDA-chiefdoms showed an increase of 7  % (3–11  %) 
and 10 % (6–15 %) at week 3 and 4 respectively post-first 
MDA but remained significantly lower throughout the 
second post-MDA weeks although the observed values 
showed increasing trend starting the second week of 
post-second MDA (Table 3; Fig. 2d).
The trend of inpatient malaria cases in the non-MDA-
chiefdoms was omitted from the analysis owing to inad-
equate hospital inpatient data (only one hospital).
Microscopic test results from the hospitals were 
excluded from the analysis due to incompleteness and 
inconsistency of the data as only few hospitals were con-
ducting microscopy during the Ebola epidemic. RDT 
records in the PHUs were complete for all-ages only, 
therefore, age-specific data analysis was omitted from 
the results. The data on parasitological confirmation 
of malaria in the VHF laboratories was incomplete and 
excluded from the analysis as most laboratories started 
Fig. 1 Map of chiefdoms in the eight districts covered by two rounds of MDA with ASAQ. a MDA by district (dark shaded); b MDA by chiefdoms 
(MDA chiefdoms—yellow shaded; and non‑MDA chiefdoms—dark-brown shaded)
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confirmation of malaria with RDT after the second MDA 
was conducted.
Figure  4 summarizes the regression trends of malaria 
indicators during the pre-MDA and post-MDA weeks in 
the MDA and non-MDA chiefdoms indicating marked 
break points of the pre- and post-MDA slopes in the 
MDA chiefdoms compared to the non-MDA chiefdoms.
In summary, the results show significant decrease in 
the key malaria indicators including suspected cases 
tested with RDT, confirmed cases, test positivity rates 
and proportion of outpatient consultations due to 
malaria during the post-MDA period compared to the 
pre-MDA period. Non-malaria cases remained relatively 
stable or increased during the post-MDA periods in the 
MDA-chiefdoms. The number of inpatient malaria cases 
also decreased moderately although statistically insig-
nificant. The Ebola alerts decreased significantly after the 
2nd round of the MDA.
However, significant reduction in trends of malaria 
indicators also occurred in the non-MDA-chiefdoms 
(controls) although the decreases were much stronger 
in the MDA-chiefdoms throughout all weeks of the two 
rounds of MDA.
Discussion
The results of the study show the impact of the MDA 
implemented in-line with the recent WHO recommen-
dations as emergency response in the Ebola affected 
countries. All logistic aspects, community and social 
mobilization efforts were addressed and put in place in 
less than 2  months. The two rounds of the MDA were 
given to  >90  % of the population, out of which 71  % 
received the anti-malarial medicines under directly-
observed treatment. The operational coverage reported 
by the NMCP during MDA is very similar to the results 
of the Independent Monitors of the MDA, a national 
survey team deployed by the MoHS immediately after 
the MDA. The monitors reported  >90  % household 
visits by drug distributors; >75 % compliance in taking 
full treatment courses; and  >74  % DOTs [14]. Assum-
ing the 71 % DOTs coverage measured on the 1st dose 
of the treatment course would be similar in all other 
treatment days of the 1st and 2nd round and assum-
ing a similar adherence to treatment among the peo-
ple who received the anti-malarials without DOTs, 
this means that at least 60 % of the population received 
full effective coverage (i.e. 0.90 x 0.71  =  60  %) with 
Table 3 Relative percent change in  malaria indicators and  Ebola alerts in  the health facilities in  MDA (n =  34 PHUs) 
and non-MDA chiefdoms (n = 14 PHUs) during post-MDA weeks using interrupted time-series regression
Percentages with asterisk are significant changes (95 % CI that excluded zero). Negative changes are decrease and positive changes are increase in trends post-MDA 
compared to trends of pre-MDA weeks
Chiefdoms Indicators Relative percent changes in 1st 
MDA round (%)
Relative percent 
changes in 2nd MDA 
round (%)
Weeks post 1st MDA Week number after sec-
ond MDA
Baseline 1 2 3 4 1 2 3 4
MDA Chiefdoms Malaria (clinical + confirmed) 603 −45* −43* −42* −10 −36* −20 −3 25
RDT tested 516 −43* −41* −36* −6 −39* −16 −31* 23
RDT positive 398 −47* −62* −53* −35* −55* −49* −58* −26*
Test positivity rate 77 −6* −35* −25* −29* −22* −35* −34* −34*
Proportion of outpatient malaria (of all‑cause outpatient) 28 −33* −57* −44* −33* −52* −60* −67* −46*
Non‑malaria 1019 −9 11 2 14 24 77 84 86
Ebola alerts 324 −30* −12 −23* −18 −48* −59* −58* −60*
Inpatient malaria cases 78 −31* −20* −9 8 −19 −26 −25 −0.6
Proportion of inpatient malaria (of all‑cause inpatients) 35 −24* −16* 16 24 −2 −70 −16 28
Non‑MDA Chiefdoms Malaria (clinical + confirmed) 290 −9* −2 −33* −26* −33* −18* −33* −39*
RDT tested 403 −23* −11* −50* −44* −43* −44* −36* −51*
RDT positive 237 −30* −9 −47* −37* −53* −38* −45* −51*
Test positivity rate 59 −8* 4 8 16* −14* 17 −7 6
Proportion of outpatient malaria (of all‑cause outpatients) 39 −33* −2 −22* −3 −37* −20* −31* −27*
Non‑malaria 374 29* −8 −20* −35 −4 −14 −2 −21
Ebola alerts 198 0.1 2 7* 10* −16* −19* −22* −32*
Page 9 of 13Aregawi et al. Malar J  (2016) 15:480 
artesunate  +  amodiaquine. Considering the timing of 
adoption and implementation; and the complexity of 
the operation amidst of the Ebola epidemic (high appre-
hension), attaining such a moderate effective coverage 
rate of MDA (covering  >2.7 million people on average 
in two rounds) is a remarkable achievement. Household 
surveys on the adverse drug reaction (ADR) during the 
MDA by teams of health workers trained in pharma-
covigilance reported common adverse drug reactions 
already described in the product information leaflet 
namely: weakness, dizziness, headaches and diarrhoea. 
But no other unexpected event was reported. A few 
deaths suspected to be associated with the MDA were 
ruled out after thorough investigations [15].
The impact of the MDA was confirmed by the sharp 
and significant reduction of the suspected malaria cases 
that were tested with RDT (>40 % decrease) immediately 
after the 1st round of MDA signifying a decrease in the 
febrile cases that would have visited the primary health 
units (PHUs). The number of RDT confirmed cases also 
declined significantly following the trend of the sus-
pected cases tested with RDT. Other indicators including 
total malaria cases (clinical and confirmed) and propor-
tion of the malaria outpatients followed the same pat-
tern. The trend of other disease conditions (non-malaria) 
was stable or increasing and as expected not influenced 
by the MDA with ASAQ. The significant decrease in the 
number of RDT tests and RDT confirmed cases in the 
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non-MDA-chiefdoms may be the result of cross-over of 
people from non-MDA-chiefdoms to the MDA-chief-
doms to benefit from the MDA. Such high population’s 
demand for medications is expected owing to the appre-
hension caused by the Ebola epidemic and is consistent 
to the report of the MDA implementation by the MoHS 
which stated that such movement could be one of the 
main reasons for stock-outs of ASAQ in the Western 
Area, Freetown during the first MDA [16].
The significant reduction in the suspected malaria 
cases tested could in principle also result in a reduction 
of suspected Ebola cases owing to the close similarities 
of clinical signs of both diseases. The benefit of the MDA 
as a temporary intervention was to offer treatment to a 
large number of malaria cases that would have been left 
untreated at home; transient prophylaxis to potential 
malaria cases; and in reducing patient case-load in the 
severely strained health facilities. In addition, as the tim-
ing of the MDA campaign coincided with the peak of the 
Ebola epidemic and high malaria transmission season, 
the number of Ebola nosocomial cases and burden of 
malaria averted could be remarkably high owing to the 
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significant decrease in the number of suspected malaria 
cases (febrile cases) and reduced number of Ebola alerts 
in the MDA-chiefdoms. The impact of the MDA on 
malaria deaths could not be measured in this study as 
all deaths, both at the service units or community level, 
were handled by the Safe Burial Teams regardless of their 
causes (Additional file  1). Nevertheless, a reduction in 
malaria-specific mortality proportional to the reduction 
of confirmed malaria cases could be expected (assuming 
the same case fatality rate).
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The impact of the MDA on the reduction of the clini-
cal malaria waned nearly after the 4th week of each MDA 
round and malaria trends returned nearly to the pre-
MDA levels coinciding with the expected maximum half-
life of 240 h (10 days) of amodiaquine [17]. The return of 
malaria to pre-intervention levels after 4 weeks of MDA 
is most likely due to re-infection of the population owing 
to high entomological inoculation levels as amodiaquine 
resistance has not yet been reported in the country [18]. 
Therefore, reduced level of malaria infection cannot be 
sustained for long with MDA in high transmission setting 
using an anti-malarial drug with moderate half-life unless 
there is a simultaneous reduction in the vectorial capac-
ity. Consistent to results of previous studies, there was no 
effect on the malaria transmission [19]. Since ASAQ has 
a relatively moderate half-life and no gametocytocidal 
drug (primaquine) was used in the campaign, no impact 
on long-term reduction of malaria transmission was 
expected. Nonetheless, in this unprecedented effort cov-
ering a very large population, the number of malaria and 
fever cases (potential nosocomial infections) were signifi-
cantly reduced as per the intention of MDA campaign. 
The effect documented in this study confirms the inten-
tion of the intervention to create a temporary reduction 
in malaria burden. A more sustained reduction of infec-
tion would require an anti-malarial medicine with longer 
half-life complemented with other aggressive interven-
tions aiming at reduction of the vectorial capacity.
The study had the following limitations: (1) reduced 
treatment seeking behaviour and testing patterns due 
to the effects of Ebola epidemic as the dynamics were 
changing over time although this had stabilized prior to 
the first MDA; (2) inability to properly estimate the pop-
ulation size (particularly in the urban districts of West-
ern Area) leading to shortage of medicines during the 
first round of MDA in two zones of Freetown which had 
lower MDA coverage; (3) cross-over of populations from 
non-MDA to the MDA-chiefdoms during the campaign 
to access treatment may be the reason for the little dif-
ference in the effect of the MDA between the MDA- and 
non-MDA-chiefdoms (Table  3); (4) implementation of 
DOTs was not measured in the first round although this 
was rectified in the second round of MDA; (5) the Ebola 
holding centres had limited testing to Ebola only at the 
VHF laboratories (no systematic parasitological testing 
for malaria). All suspected cases in the Ebola holding 
centres were treated presumptively with first-line anti-
malarial treatment without RDT testing (although some 
started testing and recording only  after the 2nd MDA); 
(6) persistence of antigenaemia for Plasmodium falci-
parum histidine-rich protein 2 (PfHRP2), such as those 
used in Sierra Leone, after treatment or recovery from 
infection (RDTs false positive) for about 40 days [20] may 
have led to underestimation of the impact of MDA on 
reducing the test positivity rate. Duration of persistent 
positivity is very long with HRP2 when compared with 
microscopy as gold standard; and short when compared 
with PCR [21]. Therefore, the value of using RDTs in 
evaluating impact of MDA on transmission reduction in 
different transmission intensity merit further studies.
Conclusion
The MDA with first-line ACT, given to more than a third 
of the population of Sierra Leone as a temporary meas-
ure in response to the Ebola outbreak at moderate levels 
of effective coverage, has resulted in significant reduction 
of malaria morbidity and of suspected malaria cases that 
would have led to Ebola nosocomial infections. The inter-
vention also helped reduce outpatient case-load to the 
strained health system at the peak of the Ebola outbreak.
As expected, the effect of the MDA on malaria burden 
and febrile cases waned quickly and malaria transmission 
returned nearly to the pre-MDA levels in about 4 weeks. 
Consistent to other studies, the intervention showed a 
relatively short-lived impact of MDA in high transmis-
sion areas when deploying medicines with moderate half-
life. From the outset, long-term impact on reduction of 
malaria transmission was not the goal. Nonetheless, the 
approach was an appropriate public health intervention 
in the context of the Ebola epidemic even in high malaria 
transmission areas of Sierra Leone. The deployment of 
MDA using medicine with moderate half-life in areas of 
high transmission in situations other than complex emer-
gencies like the Ebola epidemic in Sierra Leone would 
not be effective.
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